Has Melissa Price, MD received payments from drug or device companies?

Yes. Drug and device makers reported $290 in general payments to Melissa Price, MD across 7 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Melissa Price, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Melissa Price, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Melissa Price, MD

Endocrinology, Diabetes & Metabolism · Fishkill, NYNPI 1669678736

Payments from drug & device makers

$290in general payments, 2019–2025

Across 7 payments — averaging $41.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$123
Radius Health, Inc.$51
Mannkind Corporation$50
Davol Inc.$43
Pfizer$13
Medtronic$11

What the payments were for

Food & beverage$27796%
Education$134%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	2	$123
Radius Health, Inc.	1	$51
Mannkind Corporation	1	$50
Davol Inc.	1	$43
Pfizer	1	$13
Medtronic	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ALLODERM$109

How this compares

$290 in reported general payments places this provider in the 30th percentile of 804 endocrinology, diabetes & metabolism providers in New York.

See all endocrinology, diabetes & metabolism providers in New York →

Medicare billing

Part B allowed, 2024

$233,438

Medicare patients

459

Services billed

8,208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Tresiba Flextouch U-200Insulin Degludec	131	$284,059
OzempicSemaglutide	157	$244,990
MounjaroTirzepatide	171	$215,261
JardianceEmpagliflozin	130	$201,256
Tresiba Flextouch U-100Insulin Degludec	66	$68,475
JanuviaSitagliptin Phosphate	62	$68,091
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog	36	$48,678
TrulicityDulaglutide	32	$46,011
RybelsusSemaglutide	18	$38,005
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog	26	$36,312
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog	24	$26,880
Novolog FlexpenInsulin Aspart	44	$21,949
Humulin R U-500 KwikpenInsulin Regular, Human	14	$21,841
TradjentaLinagliptin	14	$21,601
JanumetSitagliptin Phos/Metformin Hcl	13	$20,555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AbbVieSynthroid, Armour Thyroid	$123	$21,653242 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 804 endocrinology, diabetes & metabolism providers in New York.

Other endocrinology, diabetes & metabolism in Fishkill

Chithranjan NathFishkill$174K
Robert BuschAlbany$9.1M
Anastasios ManessisNew York$4.4M
Ruth WeinstockSyracuse$3.1M
Adi CohenNew York$2.5M
Ajay ChaudhuriBuffalo$2.4M
Carol LevyNew York$2.2M
Mishaela RubinNew York$2M
Kenneth HershonNew Hyde Park$1.9M
Michael ShanikSmithtown$1.7M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →